Protein kinase inhibitors: Emerging pharmacophores 1997 - 2000

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 3, 2001, Pages 405-429

  Dumas, J ^a  

^a BAYER CORPORATION   (United States)

Author keywords

Angiogenesis; Cancer; Cell cycle; Inflammation; Kinase; MAPK; Receptor kinase

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 3 BENZOYL 4 ALKOXY PYRAZOLO PYRIDINE; 3 DIMETHYLAMINO 1 PHENYL 6 PYRIDAZONE; 3 THIENYL QUINOXALINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; AMINOPYRIDINE DERIVATIVE; CARBOMAXIDE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GW 8510; IMATINIB; IMIDAZO QUINOXALINE; IMIDAZOLE DERIVATIVE; KENPAULLONE; NEW DRUG; PAULLONE DERIVATIVE; PD 15035; PHTHALAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRAZOLOPYRIMIDINE PP2; PYRIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; RPR 101511 A; SU 9516; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VATALANIB;

ABELSON MURINE LEUKEMIA ONCOVIRUS; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; DRUG STRUCTURE; HUMAN; INFLAMMATION; PATENT; PHARMACOPHORE; PHASE 3 CLINICAL TRIAL; REVIEW;

EID: 0035117012     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.3.405     Document Type: Review

References (58)

1. Tyrosine kinase inhibitors in cancer treatment (Part II)
2. Current progress towards the development of tyrosine kinase inhibitors as anticancer agents
3. Inhibitors of tyrosine kinase involved in inflammation and autoimmune disease
4. ATP site-directed competitive and irreversible inhibitors of protein kinases
5. Strategies towards the design of novel and selective protein tyrosine kinase inhibitors
6. Recent progress towards the identification of selective inhibitors of serine/threonine protein kinases
7. Protein kinase inhibitors: Structural determinants for target specificity
8. New inhibitors of p38 kinase
9. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
10. Phenylaminopyrimidine (PAP) -derivatives: A new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors
11. Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A
12. 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular β-type platelet-derived growth factor receptor tyrosine kinase
13. Discovery of a novel, potent and src family-selective tyrosine kinase inhibitor
14. Substituted 5,7-diphenylpyrrolo [2,3d]pyrimidines: Potent inhibitors of the tyrosine kinase c-src
15. Tyrosine kinase inhibitors. 8 An unusually steep structure activity relationship for analogs of 4-(3-bromoanilino)-6,7-dimethoxy quinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor
16. A novel series of 4-phenoxyquinolines: Potent and highly selective inhibitors of PDGF receptor autophosphorylation
17. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilimo-6,7-dialkoxyquinazoline inhibitors
18. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types
19. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases
20. Identification of substituted 3-[(4,5,6,7,-tetrahydro-1H-indol-2-yl)methyl ene]-1,3,-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (flk-1/KDR), FGF-R1 and PDGF-Rβ tyrosine kinases
21. 3-Substituted indolin-2-ones are potent and selective inhibitors of cyclin-dependent kinases and exhibit effects on cell cycle and tumor growth
22. Novel cyclin dependent kinase inhibitors prevent chemotherapy-induced alopecia
23. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
24. The discovery of potent c-raf1 kinase inhibitors
25. Onxindolidene derivatives as p38 MAP kinase inhibitors
26. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
27. Design, synthesis and evaluations of substituted 3-[(3-or4-carboxy-ethylpyrrol-2-y1) methylideny1]indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases
28. P38 kinase inhibitors for the treatment of arthritis and osteoporosis: Thienyl, furyl and pyrrolyl ureas
29. Discovery of a new class of p38 kinase inhibitors
30. 1-Phenyl-5-pyrazolyl ureas: Potent and selective p38 kinase inhibitors
31. Pharmacological characterization of p38 kinase inhibitors from the urea class
32. Discovery of a new class of potent raf kinase inhibitors: Structure activity relationships
33. Potent and selective MEK inhibitors: Synthesis and SAR of 2-(4-iodo-phenylamino)benzoic acids and hydroxamic acid derivatives thereof
34. N-alkoxy-2-(4-iodo-phenylamino)-benzamides: O-alkyl benhydroxamate esters as a novel class of potent MEK inhibitors
35. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
36. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
37. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
38. Alkyl-substituted indenopyrazoles as inhibitors of cyclin-dependent kinases
39. Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors
40. Fused azepinones with antitumor activity
41. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases
42. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition
43. Paullones, a series of cyclin-dependent kinase inhibitors: Synthesis, evaluation of CDK1/cyclin B inhibition and in vitro antitumor activity
44. 2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity
45. 5-Acylpyrazolo[3,4-b]pyrimidines
46. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
47. Transformation mediated by RhoA requires activity of ROCK kinases
48. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases
49. An essential part for Rho-associated linase in the transcellular invasion of tumor cells
50. Inhibition of Rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries
51. Structure-based inhibitor design for CDK2, a cell cycle controlling protein kinase
52. Protein kinase inhibition by Staurosporine revealed in details of the molecular interaction with cdk2
53. The eucaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification
54. Protein kinase antagonists: Interim challenges and issues
55. Structure-activity relationship homology (SARAH): A conceptual framework for drug discovery in the genomic era
56. Progress in the development of inhibitors of SH2 domains